

Dimitri P Mikhailidis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6972626/dimitri-p-mikhailidis-publications-by-year.pdf>

Version: 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

808
papers

25,216
citations

76
h-index

118
g-index

942
ext. papers

29,414
ext. citations

4
avg, IF

7.23
L-index

#	Paper	IF	Citations
808	The burden of carotid-related strokes.. <i>Annals of Translational Medicine</i> , 2022 , 10, 159	0.8	0
807	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress.. <i>Biomarker Insights</i> , 2022 , 17, 11772719211066791	1.1	
806	C-reactive protein-albumin ratio and erectile dysfunction.. <i>Andrologia</i> , 2022 , e14386	0.7	
805	Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks.. <i>Journal of Stroke</i> , 2022 , 24, 163-165	1.7	
804	Prevalence of statin intolerance: a meta-analysis.. <i>European Heart Journal</i> , 2022 ,	3.5	8
803	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies.. <i>Archives of Medical Science</i> , 2022 , 18, 604-616	0.8	3
802	Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term.. <i>Circulation Research</i> , 2022 , CIRCRESAHA121320460	5.2	5
801	Alice through the Looking-glass: Can We Improve Peer Review?. <i>International Journal of Lower Extremity Wounds</i> , 2022 , 15347346221084784	0.4	1
800	Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis.. <i>Angiology</i> , 2022 , 33197221081914	0.6	0
799	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.. <i>Hypertension</i> , 2022 , 101161HYPERTENSIONAHA12217982	2.4	7
798	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation.. <i>Metabolism: Clinical and Experimental</i> , 2022 , 132, 155211	2.7	0
797	A Call to Encourage Participation in the Reviewing Process: The REFEREE Acrostic.. <i>International Journal of Lower Extremity Wounds</i> , 2022 , 15347346221102645	0.4	1
796	Statin use and renal function after aortic aneurysm repair procedures. <i>Journal of Vascular Surgery</i> , 2021 , 74, 2121-2122	0.7	1
795	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2021 , 1	1.2	1
794	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. <i>PLoS ONE</i> , 2021 , 16, e0260313	1.2	2
793	Incidence of contrast-induced acute kidney injury in patients with acute mesenteric ischemia and identification of potential predictive factors. <i>Vascular</i> , 2021 , 17085381211050766	0.3	
792	Comment on "Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women and Men: The Challenges Remain". <i>Annals of Surgery</i> , 2021 , 274, e857-e858	1.4	

791	Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 31, 106182	0.8	3
790	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. <i>Molecular Metabolism</i> , 2021 , 50, 101049	2.3	12
789	Homocysteine and diabetes: Role in macrovascular and microvascular complications. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107834	0.9	8
788	Endocan: a new marker of endothelial function. <i>Current Opinion in Cardiology</i> , 2021 , 36, 462-468	0.6	4
787	Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 415-436	0.9	6
786	Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. <i>Archives of Medical Science</i> , 2021 , 17, 739-751	0.8	0
785	Management of Patients with Asymptomatic Carotid Stenosis May Need to Be Individualized: A Multidisciplinary Call for Action. <i>Journal of Stroke</i> , 2021 , 23, 202-212	1.7	5
784	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021 , 119, 154770	2.7	20
783	Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1941-1951	1	7
782	The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review. <i>Andrology</i> , 2021 , 9, 1504-1511	1.4	0
781	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2021 , 6, CD003748	1.6	2
780	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021 , 67, 40-52	1.9	14
779	Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 2. <i>Current Vascular Pharmacology</i> , 2021 ,	1.1	1
778	Narrative Review of Carotid disease and the kidney. <i>Annals of Translational Medicine</i> , 2021 , 9, 1210	0.8	0
777	Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1. <i>Current Vascular Pharmacology</i> , 2021 ,	1.1	1
776	Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021 , 129, 699-704	0.5	4
775	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021 , 40, 255-276	1.5	23
774	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 51-58	0.9	3

773	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment Options. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 25-39	0.9	6
772	More Good News on Statins and COVID-19. <i>American Journal of Cardiology</i> , 2021 , 138, 127-128	0.7	6
771	The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 991-1001	0.7	2
770	Management of patients with asymptomatic carotid stenosis may need to be individualized: a multidisciplinary call for action. Republication of J Stroke 2021;23:202-212. <i>International Angiology</i> , 2021 , 40, 487-496	0.4	2
769	Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. <i>Current Vascular Pharmacology</i> , 2021 ,	1.1	3
768	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). <i>Current Vascular Pharmacology</i> , 2021 , 19, 469-486	1.1	2
767	Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2021 , 19, 469-486	1.1	3
766	Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14833	0.7	2
765	Inflammatory Markers Associated With Diabetes Mellitus - Old and New Players. <i>Current Pharmaceutical Design</i> , 2021 , 27, 3020-3035	1	6
764	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. <i>Clin Res Hepatol</i>	0.5	
763	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107619	0.9	7
762	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <i>Archives of Medical Science</i> , 2020 , 16, 485-489	0.8	54
761	Vascular surgical procedures in patients with familial hypercholesterolaemia: is it too late?. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1255	0.7	
760	Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. <i>Archives of Medical Science</i> , 2020 , 16, 260-272	0.8	4
759	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020 , 33, 155-179	1.3	20
758	Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. <i>Metabolism: Clinical and Experimental</i> , 2020 , 109, 154305	2.7	4
757	Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. <i>Journal of Clinical Medicine</i> , 2020 , 9,	1.5	3
756	Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2020 , 36, 731-740	0.7	8

755	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020 , 155, 104719	2.5	7
754	Excessive "orthotopic" fat accumulation: Links with cardiometabolic diseases and potential drug treatment. <i>Journal of Cellular Physiology</i> , 2020 , 235, 6321-6322	1.9	6
753	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. <i>Endocrine</i> , 2020 , 69, 249-261	1	9
752	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2020 , 27, 1021-1040	1.3	10
751	Perivascular adipose tissue in cardiovascular diseases. <i>Anatolian Journal of Cardiology</i> , 2020 , 23, 58	0.2	1
750	Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. <i>Clinical Nutrition</i> , 2020 , 39, 3730-3735	1.5	0
749	Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5637-5649	1	4
748	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020 , 42, e15-e24	0.5	7
747	Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study. <i>Clinical Nutrition</i> , 2020 , 39, 2730-2733	1.5	2
746	Rationale for screening selected patients for asymptomatic carotid artery stenosis. <i>Current Medical Research and Opinion</i> , 2020 , 36, 361-365	0.7	8
745	Low-carbohydrate diet: forget restriction, replace with balance!. <i>European Heart Journal</i> , 2020 , 41, 1058	3.5	5
744	Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study. <i>Journal of the American College of Nutrition</i> , 2020 , 39, 407-413	0.9	5
743	Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. <i>Annals of Translational Medicine</i> , 2020 , 8, 1265	0.8	2
742	Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. <i>Metabolites</i> , 2020 , 10,	1.5	3
741	Diabetes and carotid artery disease: a narrative review. <i>Annals of Translational Medicine</i> , 2020 , 8, 1280	0.8	5
740	Adverse Impact of spp. and Beneficial Role of spp. on Renal Function: Insights from a Mendelian Randomization Analysis. <i>Nutrients</i> , 2020 , 12,	2	5
739	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2125-2135	0.9	6
738	Half a century and more of PhD theses by published papers: Comment on: "Bringing the doctoral thesis by published papers to the Social Sciences and the Humanities: A quantitative easing? A small study of doctoral thesis submission rules and practice in two disciplines in the UK" by John Rigby and Barbara Jones in published online 15 May 2020. <i>Scientometrics</i> , 2020 , 125, 1-4	1	1

737	CETP inhibition in the REVEAL trial: could we aim higher?. <i>Archives of Medical Science</i> , 2020 , 16, 1229-1230	0.8	1
736	NAFLD and Statins. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3052-3053	0.8	1
735	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. <i>Angiology</i> , 2020 , 71, 10-16	0.6	17
734	Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. <i>Atherosclerosis</i> , 2020 , 296, 49-58	0.8	14
733	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020 , 39, 3677-3686	1.5	18
732	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020 , 71, 689-697	0.6	11
731	Increased risk for cardiovascular disease in patients with obstructive sleep apnoea syndrome-chronic obstructive pulmonary disease (overlap syndrome). <i>Clinical Respiratory Journal</i> , 2019 , 13, 708-715	0.5	8
730	Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107408	0.9	4
729	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States. <i>Nutrients</i> , 2019 , 11,	2	9
728	Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome. <i>Medicina (Lithuania)</i> , 2019 , 55,	0.9	5
727	Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. <i>Journal of the American College of Nutrition</i> , 2019 , 38, 552-563	0.9	18
726	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019 , 17, 538-540	1.1	18
725	Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. <i>European Heart Journal</i> , 2019 , 40, 2870-2879	3.5	47
724	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 918-928	3.2	53
723	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 465-467	0.9	6
722	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019 , 143, 1-16	2.5	54
721	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, 92-100	2.7	32
720	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019 , 115, 204-212	2.5	25

7 ¹⁹	Statin use in patients with diabetes: one drug, multiple benefits. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 839-840	0.6	2
7 ¹⁸	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2007-2017	0.9	14
7 ¹⁷	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. <i>Journal of the American College of Nutrition</i> , 2019 , 38, 633-639	0.9	7
7 ¹⁶	Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data. <i>British Journal of Nutrition</i> , 2019 , 122, 1262-1270	0.9	8
7 ¹⁵	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019 , 18, 188	1.3	13
7 ¹⁴	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. <i>Metabolism: Clinical and Experimental</i> , 2019 , 101, 154001	2.7	37
7 ¹³	Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2051-2059	1	23
7 ¹²	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019 , 17, 515-537	1.1	12
7 ¹¹	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019 , 17, 498-514	1.1	23
7 ¹⁰	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. <i>Archives of Medical Science</i> , 2019 , 15, 1357-1364	0.8	16
7 ⁰⁹	Mean platelet volume and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2019 , 34, 390-398	0.6	22
7 ⁰⁸	Endocan and Erectile Dysfunction. <i>American Journal of Men's Health</i> , 2019 , 13, 1557988319893889	0.6	4
7 ⁰⁷	Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. <i>Atherosclerosis</i> , 2019 , 284, 44-49	0.8	12
7 ⁰⁶	Consumption of dairy product and its association with total and cause-specific mortality - A population-based cohort study and meta-analysis. <i>Clinical Nutrition</i> , 2019 , 38, 2833-2845	1.5	31
7 ⁰⁵	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019 , 286, 226-233	0.8	16
7 ⁰⁴	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. <i>International Journal of Cardiology</i> , 2019 , 276, 242-247	0.8	16
7 ⁰³	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019 , 284, 129-135	0.8	6
7 ⁰²	A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study. <i>British Journal of Nutrition</i> , 2019 , 121, 1294-1302	0.9	7

701	Prehypertension, the Risk of Hypertension and Events. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019 , 37-55	0	
700	Dietary inflammatory index and cardiometabolic risk in US adults. <i>Atherosclerosis</i> , 2018 , 276, 23-27	0.8	40
699	Statin Intolerance: Some Practical Hints. <i>Cardiology Clinics</i> , 2018 , 36, 225-231	0.8	26
698	Carotid Bifurcation Geometry as Assessed by Ultrasound is Associated with Early Carotid Atherosclerosis. <i>Annals of Vascular Surgery</i> , 2018 , 51, 207-216	0.4	6
697	Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. <i>Trends in Pharmacological Sciences</i> , 2018 , 39, 331-353	3.4	13
696	The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 427-435	1.8	23
695	Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 565-569	0.9	19
694	Statin loading in cardiovascular surgery: never too early to treat. <i>Current Opinion in Cardiology</i> , 2018 , 33, 436-443	0.6	18
693	Cardiovascular Risk Factors and Peripheral Arterial Disease 2018 , 189-200		
692	Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Drugs</i> , 2018 , 78, 453-462	3.3	36
691	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 801-809	1.2	15
690	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 279-286	0.9	21
689	Carotid Artery Stenting Has a Role in the Management of Asymptomatic Carotid Stenosis, but This Is Currently Small. <i>Angiology</i> , 2018 , 69, 640-641	0.6	
688	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018 , 39, 19-26	1.2	12
687	The link between insulin resistance parameters and serum uric acid is mediated by adiposity. <i>Atherosclerosis</i> , 2018 , 270, 180-186	0.8	38
686	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 259-278	1.3	5
685	Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. <i>Annals of Medicine</i> , 2018 , 50, 1-6	1.2	53
684	Appropriate Patient Selection for Carotid Revascularization Procedures is Urgently Needed. <i>Angiology</i> , 2018 , 69, 12-16	0.6	5

683	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018 , 58, 2549-2556	3	41
682	Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 266-270	0.9	56
681	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018 , 272, 316-322	0.8	10
680	Mean Platelet Volume and Platelet Distribution Width in Patients With Obstructive Sleep Apnea Syndrome and Concurrent Chronic Obstructive Pulmonary Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 1216-1222	0.8	10
679	Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit?. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 982-984	0.9	12
678	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018 , 50, 565-575	1.2	29
677	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 875-892	0.9	12
676	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 893-915	0.9	5
675	Leptin, cardiovascular diseases and type 2 diabetes mellitus. <i>Acta Pharmacologica Sinica</i> , 2018 , 39, 1176-1188	1.1	112
674	Statins and substantially increased ALT values at baseline. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12444	0.8	
673	Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Current Pharmaceutical Design</i> , 2018 , 24, 1034-1040	1	2
672	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 219-227	1.1	51
671	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Drugs</i> , 2018 , 78, 99-109	3.3	30
670	Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. <i>British Journal of Nutrition</i> , 2018 , 120, 1272-1278	0.9	12
669	Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018 , 9, 1023-1033	1.9	55
668	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018 , 17, 461-478	1	5
667	Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES. <i>Lipids in Health and Disease</i> , 2018 , 17, 219	1.3	8
666	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. <i>European Heart Journal</i> , 2018 , 39, 3635-3640	3.5	18

665	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 96-118	3.8	157
664	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017 , 68, 99-108	0.6	23
663	Marital Status, Cardiovascular Diseases, and Cardiovascular Risk Factors: A Review of the Evidence. <i>Journal of Womens Health</i> , 2017 , 26, 624-632	1	64
662	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 17-32	2.7	152
661	Semaglutide, lipid-lowering drugs, and NAFLD. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 329-330	4.9	10
660	Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> 2016;39:1684-1692. <i>Diabetes Care</i> , 2017 , 40, e46	3.9	1
659	Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. <i>Current Opinion in Cardiology</i> , 2017 , 32, 422-429	4.7	18
658	Adiponectin, lipids and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2017 , 28, 347-354	1.3	87
657	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 972-985.e9	1.2	21
656	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor- α concentrations: A systematic review and meta-analysis of controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1458-1464	0.9	18
655	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, G681-G682	1.3	3
654	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017 , 122, 105-117	2.5	16
653	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017 , 75, 307-326	1.7	183
652	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017 , 75, 361-373	1.7	30
651	The impact of metabolic syndrome and its components on perioperative outcomes after elective laparotomy - A prospective observational study. <i>American Journal of Surgery</i> , 2017 , 214, 831-837	0.7	5
650	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017 , 66, e6	2.7	1
649	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017 , 75, 731-767	1.7	186
648	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017 , 13, 965-1005	0.8	173

647	Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. <i>International Journal of COPD</i> , 2017 , 12, 443-450	0.8	16
646	Homocysteine and Non-Cardiac Vascular Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 3224-3232	1	18
645	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , 2017 , 16, 192	1.3	34
644	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. <i>Lipids in Health and Disease</i> , 2017 , 16, 254	1.3	20
643	Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. <i>Archives of Medical Science</i> , 2017 , 13, 53-60	0.8	20
642	More on carotid atherosclerosis and ezetimibe. <i>International Angiology</i> , 2017 , 36, 580-581	0.4	6
641	Time for new low density lipoprotein cholesterol (LDL-C) targets?. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1539-1541	0.9	2
640	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 419-431	1.1	30
639	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017 , 124, 64-73	2.5	3
638	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1243-1260	0.9	30
637	Carotid Bifurcation Geometry and Atherosclerosis. <i>Angiology</i> , 2017 , 68, 757-764	0.6	23
636	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017 , 66, e1-e2	2.7	5
635	The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters. <i>Angiology</i> , 2017 , 68, 381-388	0.6	25
634	Contrast-Induced Acute Kidney Injury in Patients Undergoing Carotid Artery Stenting: An Underestimated Issue. <i>Angiology</i> , 2017 , 68, 752-756	0.6	19
633	Lipoprotein (a) and Cardiovascular Risk: The Show Must go on. <i>Current Medicinal Chemistry</i> , 2017 , 24, 989-1006	1.3	15
632	Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1522-1532	1	31
631	The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?. <i>Current Opinion in Lipidology</i> , 2017 , 28, 88-89	1.3	1
630	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016 , 64, 241-2	3.5	7

629	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016 , 5,	1.4	141
628	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. <i>Clinical Endocrinology</i> , 2016 , 85, 694-695	0.9	1
627	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016 , 6, 30060	1.5	21
626	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1513-4	0.7	13
625	Coronary Artery Bypass Grafting Combined with Open Versus Endovascular Abdominal Aortic Aneurysm Repair. <i>Annals of Vascular Surgery</i> , 2016 , 33, 263-4	0.4	
624	C-reactive protein levels and aortic aneurysmal disease progression after endovascular repair: The jury is still out. <i>International Journal of Cardiology</i> , 2016 , 203, 1141	0.8	1
623	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016 , 14, 4	2.9	51
622	Impact of comorbidity on outcome in kidney transplant recipients: a retrospective study in Italy. <i>Internal and Emergency Medicine</i> , 2016 , 11, 825-32	0.9	7
621	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016 , 111, 343-356	2.5	16
620	The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 405-11	0.8	176
619	Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis. <i>Angiology</i> , 2016 , 67, 411-9	0.6	46
618	Does bilirubin protect against developing diabetes mellitus?. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 728-37	0.9	4
617	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016 , 23, 1175-81	2.3	29
616	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016 , 103, 236-52	2.5	49
615	Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Angiology</i> , 2016 , 67, 749-55	0.6	48
614	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 369-80	0.9	35
613	All for Statins and Statins for All; An Update. <i>Current Pharmaceutical Design</i> , 2016 , 22, 18-27	1	14
612	Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. <i>Current Pharmaceutical Design</i> , 2016 , 22, 2723-5	1	6

611	Lipids, Statins and Heart Failure: An Update. <i>Current Pharmaceutical Design</i> , 2016 , 22, 4796-4806	1	15
610	Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2016 , 14, 432-441	1.1	34
609	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1639-1640	0.7	1
608	Obstructive sleep apnea and cardiovascular disease: Is mean platelet volume one of the links?. <i>Anatolian Journal of Cardiology</i> , 2016 , 16, 223	0.2	1
607	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 520-32	1.8	110
606	Statins induce regression of carotid artery stenosis: Fact or fiction?. <i>International Journal of Cardiology</i> , 2016 , 220, 680	0.8	3
605	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016 , 6, 19188	1.5	38
604	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016 , 107, 360-371	2.5	49
603	Statins, renal function and homocysteine. <i>Pharmacological Reports</i> , 2016 , 68, 1093	1.3	
602	Lipid-modifying effects of nutraceuticals: An evidence-based approach. <i>Nutrition</i> , 2016 , 32, 1179-92	1.2	133
601	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1109-23	2.7	212
600	Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1163-71	1.2	17
599	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016 , 253, 194-208	0.8	117
598	All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used?. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 46-52	0.5	9
597	Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015 , 99, 329-36	2.5	105
596	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015 , 242, 87-96	0.8	37
595	Mean platelet volume in patients undergoing percutaneous coronary intervention. <i>Platelets</i> , 2015 , 26, 269-70	0.9	4
594	In reply--Coenzyme Q10 and statin-induced myopathy. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 420-1	1.5	6

593	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015 , 189, 47-55	0.8	110
592	Hyperuricaemia in cardiovascular diseases: a passive or an active player?. <i>Medical Principles and Practice</i> , 2015 , 24, 269-70	1	8
591	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 935-55	0.9	94
590	Strategies to overcome statin intolerance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 851-5	1.2	12
589	Statins and Niacin: The End of Residual Risk Therapy? 2015 , 37-43		1
588	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. <i>Atherosclerosis</i> , 2015 , 241, 507-22	0.8	420
587	Abdominal aortic aneurysms and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1330-6	0.9	35
586	Should we consider ezetimibe to reach even lower LDL-C targets?. <i>Current Medical Research and Opinion</i> , 2015 , 31, 459-60	0.7	5
585	Endocan: A novel inflammatory indicator in cardiovascular disease?. <i>Atherosclerosis</i> , 2015 , 243, 339-43	0.8	123
584	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 471-2	0.5	3
583	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom? 2015 , 179-190		1
582	Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes. <i>Nephron</i> , 2015 , 131, 34-42	0.7	19
581	An evaluation of RVX-208 for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1389-98	1.8	25
580	Contrast-Induced Nephropathy: An "All or None" Phenomenon?. <i>Angiology</i> , 2015 , 66, 508-13	0.6	81
579	Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015 , 178, 111-6	0.8	129
578	Do we need guideline-driven specific lipid goals to achieve regression of coronary atherosclerosis and maximize therapy benefits?. <i>American Journal of Cardiology</i> , 2015 , 115, 280	0.7	
577	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , 2015 , 238, 182-4	0.8	0
576	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 142-5	0.9	12

575	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015 , 13, 229	2.9	126
574	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015 , 5, 9902	1.5	109
573	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015 , 30, 416-21	0.6	26
572	Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 546-57	1.8	110
571	Dysfunctional high-density lipoprotein: not only quantity but first of all quality?. <i>Archives of Medical Science</i> , 2015 , 11, 230-1	0.8	6
570	Ear lobe crease: a marker of coronary artery disease?. <i>Archives of Medical Science</i> , 2015 , 11, 1145-55	0.8	17
569	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6820-34	1.3	91
568	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7860-8	1.3	97
567	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015 , 11, 1-23	0.8	252
566	Effects of oral hypoglycemic agents on platelet function. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 846-51	0.9	19
565	A possible relationship between renal impairment and complications development in type 2 diabetes mellitus: a prospective, observational study in Italy. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 771-5	0.9	2
564	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015 , 241, 433-42	0.8	107
563	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1449-61	0.9	33
562	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , 2015 , 31, 221-8	0.7	16
561	Endocan and atherosclerosis. <i>Angiology</i> , 2015 , 66, 490	0.6	17
560	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 603-10	1.8	13
559	Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 24-34	1.5	139
558	Statins and Fibrates: Should They Be Recommended? 2015 , 11-23		1

557	Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. <i>Nature Reviews Cardiology</i> , 2014 , 11, 72-4	4.9	13
556	Therapy: Caloric and fat intake in statin users. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 450-1	4.1	1
555	ETC-1002: a future option for lipid disorders?. <i>Atherosclerosis</i> , 2014 , 237, 705-10	0.8	33
554	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 912	0.9	3
553	Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. <i>Angiology</i> , 2014 , 65, 773-7	0.6	112
552	Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. <i>American Journal of Clinical Dermatology</i> , 2014 , 15, 137-42	1.9	27
551	Regarding "Progression of asymptomatic carotid stenosis despite optimal medical therapy". <i>Journal of Vascular Surgery</i> , 2014 , 59, 1752-3	0.7	3
550	Implications of the timely diagnosis of lower extremity peripheral arterial disease. <i>International Journal of Cardiology</i> , 2014 , 173, 551	0.8	
549	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 74-82		64
548	The effects of antiepileptic drugs on vascular risk factors: a narrative review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014 , 23, 677-84	0.8	46
547	Serum endocan levels as a marker of disease activity in patients with Behçet disease. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 291-6	0.9	107
546	¹⁸ F-fluorodeoxyglucose uptake in abdominal aortic aneurysms: a useful biomarker of AAA rupture risk. <i>BioMed Research International</i> , 2014 , 2014, 930738	0.9	1
545	Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI. <i>Nature Reviews Nephrology</i> , 2014 , 10, 8-9	4.3	21
544	Risk of illness, hospitalization and death in a cohort of blood donors in Italy. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1803-12	0.7	5
543	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2014 , CD003748	1.6	69
542	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014 , 29, 389-95	0.6	26
541	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 361	4.9	6
540	The role of statins in the treatment of type 2 diabetes mellitus: an update. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3665-74	1	31

539	Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. <i>Current Pharmaceutical Design</i> , 2014 , 20, 4944-52	1	31
538	Psoriasis and Vascular Risk : An Update. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6114-25	1	14
537	Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6299-305	1	15
536	Alcohol and the cardiovascular system: a double-edged sword. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6276-88	1	21
535	Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6350-7	1	6
534	Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. <i>Current Vascular Pharmacology</i> , 2014 , 12, 505-11	1.1	24
533	Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. <i>Current Vascular Pharmacology</i> , 2014 , 12, 627-41	1.1	36
532	Ageing mechanisms and associated lipid changes. <i>Current Vascular Pharmacology</i> , 2014 , 12, 682-9	1.1	11
531	The challenges in moving from ageing to successful longevity. <i>Current Vascular Pharmacology</i> , 2014 , 12, 662-73	1.1	15
530	Uric acid metabolism in pre-hypertension and the metabolic syndrome. <i>Current Vascular Pharmacology</i> , 2014 , 12, 572-85	1.1	12
529	Angiotensin II increases corpus cavernosal contractility and oxidative stress in partial bladder outlet obstructed rabbits: relevance to erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1251-8	0.4	3
528	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. <i>Lipids in Health and Disease</i> , 2013 , 12, 47	1.3	20
527	Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. <i>Diabetology and Metabolic Syndrome</i> , 2013 , 5, 13	1.5	37
526	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. <i>Internal and Emergency Medicine</i> , 2013 , 8, 735-40	0.9	26
525	Renal dysfunction and all-cause mortality in cardio-renal syndrome: calculation of glomerular filtration rate is crucial, independent of the equation. <i>International Journal of Cardiology</i> , 2013 , 170, e11-3 ⁸	0.8	1
524	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013 , 168, 5437-47	0.8	53
523	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 21-33	2.7	66
522	Summarizing the FIELD study: lessons from a 'negative' trial. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2601-10	0.9	9

521	The effect of biological age on the metabolic responsiveness of mice fed a high-fat diet. <i>Laboratory Animals</i> , 2013 , 47, 241-4	0.8	11
520	The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013 , 168, 2816-24	0.8	32
519	Alcohol consumption and the heart. <i>International Journal of Cardiology</i> , 2013 , 168, 4319	0.8	
518	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. <i>Current Medical Research and Opinion</i> , 2013 , 29, 1263-74	0.7	60
517	Metabolic syndrome and renal disease. <i>International Journal of Cardiology</i> , 2013 , 164, 141-50	0.8	52
516	Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. <i>International Journal of Cardiology</i> , 2013 , 168, 4528	0.8	3
515	PCSK9 inhibition - a novel mechanism to treat lipid disorders?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3869-77	1	38
514	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013 , 72, 35-44	2.5	76
513	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 88	1.2	2
512	Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- β -lowering property". <i>Digestive and Liver Disease</i> , 2013 , 45, 82-3	0.8	
511	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013 , 29, 435-51	0.7	29
510	Why calls for more routine carotid stenting are currently inappropriate: an international, multispecialty, expert review and position statement. <i>Stroke</i> , 2013 , 44, 1186-90	1.8	38
509	Additional issues on screening, prevention, and treatment of abdominal aortic aneurysms. <i>American Journal of Men's Health</i> , 2013 , 7, 472-4	0.6	2
508	Epicardial fat and vascular risk: a narrative review. <i>Current Opinion in Cardiology</i> , 2013 , 28, 458-63	0.6	53
507	Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. <i>Angiology</i> , 2013 , 64, 173-80	0.6	16
506	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. <i>Clinical Lipidology</i> , 2013 , 8, 509-512		
505	Platelet cholesterol: from man to seal. <i>Platelets</i> , 2013 , 24, 253-4	0.9	
504	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013 , 28, 452-7	0.6	19

503	Statin therapy and new-onset diabetes: an attempt at recommendations. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 213-216	0.8	8
502	Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. <i>Clinical Cardiology</i> , 2013 , 36, 364-5	0.7	4
501	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2013 , 11, 112-120	1.1	20
500	Statins and Infrainguinal Vascular Bypass Procedures. <i>Current Vascular Pharmacology</i> , 2013 , 11, 51-57	1.1	8
499	Hyperuricaemia: more than just a cause of gout?. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 397-402	0.6	58
498	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013 , 9, 788-95	0.8	19
497	The role of fibrate treatment in dyslipidemia: an overview. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3124-31		82
496	Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. <i>Nutrients</i> , 2013 , 5, 928-48	2	92
495	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013 , 9, 418-26	0.8	28
494	Subclinical hypothyroidism and vascular risk: an update. <i>Hormones</i> , 2013 , 12, 495-506	1	21
493	Colesevelam: a new and improved bile acid sequestrant?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3115-23		14
492	Uric acid and diabetes: Is there a link?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4930-7	1	60
491	A review of the cardiovascular and anti-atherogenic effects of ghrelin. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4953-63	1	18
490	Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4964-80	1	10
489	Pioglitazone and cancer: angel or demon?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4913-29	1	25
488	Ezetimibe therapy for dyslipidemia: an update. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3107-14	1	31
487	Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3766-72	1	4
486	Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3858-68	1	34

485	The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Current Vascular Pharmacology</i> , 2013 , 11, 779-84	1.1	15
484	Hemostatic factors and the metabolic syndrome. <i>Current Vascular Pharmacology</i> , 2013 , 11, 880-905	1.1	29
483	Ezetimibe - a new approach in hypercholesterolemia management. <i>Pharmacological Reports</i> , 2012 , 64, 997-8	1.3	4
482	Welcome to CMROB 40th Anniversary Issue. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1-1	0.7	36
481	Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. <i>American Journal of Cardiology</i> , 2012 , 110, 763	0.7	4
480	Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. <i>Journal of Hepatology</i> , 2012 , 57, 476	3.5	4
479	Comparison of the five 2011 guidelines for the treatment of carotid stenosis. <i>Journal of Vascular Surgery</i> , 2012 , 55, 1504-8	0.7	41
478	The meaning of hypokalemia in heart failure. <i>International Journal of Cardiology</i> , 2012 , 158, 12-7	0.8	48
477	Carotid artery stenting: "good news" or "bad news" for post-procedural cognitive function?. <i>International Journal of Cardiology</i> , 2012 , 157, 156	0.8	
476	Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , 2012 , 12, 143-56	0.9	35
475	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 93	1.2	1
474	Heparin and platelet activation. <i>Thrombosis Research</i> , 2012 , 130, 685; author reply 686	1.7	
473	Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012 , 51, 314-24	4.5	160
472	Regarding "Estimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repair". <i>Journal of Vascular Surgery</i> , 2012 , 56, 1829; author reply 1829	0.7	1
471	Statins and Infrainguinal Vascular Bypass Procedures. <i>Current Vascular Pharmacology</i> , 2012 , 11, 51-57	1.1	1
470	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2012 , 11, 112-120	1.1	3
469	Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 88-97	0.1	8
468	State of the art paper The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. <i>Archives of Medical Science</i> , 2012 , 6, 970-977	0.8	6

467	Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012 , 8, 598-600	0.8	16
466	The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , 2012 , 8, 6-10	0.8	3
465	Obstructive sleep apnoea syndrome and cardiovascular risk. <i>Archives of Medical Science</i> , 2012 , 8, 1115-6	0.8	13
464	Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Brain and Behavior</i> , 2012 , 2, 200-7	0.9	3
463	Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'. <i>Clinical Cardiology</i> , 2012 , 35, 315; author reply 316-7	0.7	2
462	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 1109	0.8	6
461	Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. <i>Clinical Endocrinology</i> , 2012 , 76, 177-8	0.9	7
460	Statins in patients with renal dysfunction. <i>American Journal of Cardiology</i> , 2012 , 109, 1537	0.7	6
459	Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Vascular</i> , 2012 , 20, 1-7	0.3	1
458	Why the US Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Angiology</i> , 2012 , 63, 639-44	0.6	3
457	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. <i>Angiology</i> , 2012 , 63, 358-66	0.6	21
456	Triglycerides: a case for treatment?. <i>Current Opinion in Cardiology</i> , 2012 , 27, 398-404	0.6	24
455	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012 , 27, 392-7	0.6	17
454	Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012 , 18, 113-4	0.8	
453	Lipid lowering agents and the endothelium: an update after 4 years. <i>Current Vascular Pharmacology</i> , 2012 , 10, 33-41	1.1	16
452	Dronedarone: an overview. <i>Annals of Medicine</i> , 2012 , 44, 60-72	1.2	14
451	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 287-8; author reply 289-90	0.9	3
450	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012 , 8, 813-7	0.5	2

449	Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012 , 17, 427; author reply 428	0.9	2
448	Near-infrared spectroscopy assessment following exercise training in patients with intermittent claudication and in untrained healthy participants. <i>Vascular and Endovascular Surgery</i> , 2012 , 46, 315-24	0.3	32
447	Prevalence of metabolic syndrome according to different definitions in a hypertensive population. <i>Angiology</i> , 2012 , 63, 39-47	0.6	13
446	Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. <i>Oman Medical Journal</i> , 2012 , 27, 260	0.5	1
445	Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. <i>Clinical Lipidology</i> , 2012 , 7, 259-262		2
444	Lipids and non-cardiac vascular disease: a lecture overview. <i>Current Vascular Pharmacology</i> , 2012 , 10, 743-4	1.1	0
443	Hypertension and kidney disease: is renalase a new player or an innocent bystander?. <i>Journal of Hypertension</i> , 2012 , 30, 457-62	0.5	16
442	Should raising high-density lipoprotein cholesterol be a matter of debate?. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 254-9	0.6	11
441	An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , 2012 , 30, 1681-9	0.5	43
440	Re: biomedical publications profile and trends in gulf cooperation council countries. <i>Sultan Qaboos University Medical Journal</i> , 2012 , 12, 378-9	0.3	
439	The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. <i>Archives of Medical Science</i> , 2012 , 8, 970-7	0.8	10
438	Gender and Socio-economic Differences in Daily Smoking and Smoking Cessation Among Adult Residents in a Greek Rural Area. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 15-21	0.1	10
437	Weekend versus weekday, morning versus evening admission in relationship to mortality in acute coronary syndrome patients in 6 middle eastern countries: results from gulf race 2 registry. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 106-12	0.1	4
436	Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 122-5	0.1	5
435	The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 147-55	0.1	15
434	Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. <i>Oman Medical Journal</i> , 2012 , 27, 177	0.5	1
433	Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2011 , 27, 1191-210	0.7	61
432	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 647-55	0.9	24

431	Peroxisome proliferator-activated receptors and atherosclerosis. <i>Angiology</i> , 2011 , 62, 523-34	0.6	25
430	Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 401-20	1.5	36
429	Acute pancreatitis in pregnancy: an overview. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011 , 159, 261-6	0.6	64
428	Statins and contrast-induced nephropathy: issues requiring further investigation. <i>International Journal of Cardiology</i> , 2011 , 151, 364	0.8	4
427	Optimal statin type and dosage for vascular patients. <i>Journal of Vascular Surgery</i> , 2011 , 53, 837-44	0.7	22
426	Carotid artery stenting may be contraindicated in female patients with symptomatic carotid artery stenosis. <i>Journal of Vascular Surgery</i> , 2011 , 54, 1870-1; author reply 1871	0.7	
425	Nutrition During Pregnancy and the Effect of Carbohydrates on the Offspring's Metabolic Profile: In Search of the "Perfect Maternal Diet". <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 103-9	0.1	32
424	Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. <i>Journal of Urology</i> , 2011 , 185, 2414-20	0.6	12
423	Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. <i>Atherosclerosis</i> , 2011 , 214, 11-9	0.8	23
422	Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. <i>Clinical Biochemistry</i> , 2011 , 44, 1457-63	0.8	29
421	Best medical treatment for a symptomatic carotid artery stenosis. <i>Lancet, The</i> , 2011 , 377, 123; author reply 123-4	11.5	1
420	Raised liver enzymes in patients taking statins [Authors' reply]. <i>Lancet, The</i> , 2011 , 377, 1075-1076	11.5	1
419	Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 85-9	0.1	7
418	Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 24-34	0.1	44
417	Assessing renal function - searching for the perfect marker continues!. <i>Archives of Medical Science</i> , 2011 , 7, 565-7	0.8	13
416	Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , 2011 , 7, 1067-75	0.8	9
415	Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 203-9	0.1	11
414	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary heart disease risk factors by multifactorial interVENTion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011 , 7, 984-92	0.8	35

413	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011 , 7, 796-805	0.8	51
412	Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 153-63	0.1	104
411	Ideal lipid profile and genes for an extended life span. <i>Current Opinion in Cardiology</i> , 2011 , 26, 348-55	0.6	11
410	Left atrial size in hypertension and stroke. <i>Journal of Hypertension</i> , 2011 , 29, 1988-93	0.5	32
409	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. <i>Journal of Hypertension</i> , 2011 , 29, 2493-4; author reply 2494	0.5	23
408	Pulmonary arterial hypertension and statins: an update. <i>Current Opinion in Cardiology</i> , 2011 , 26, 322-6	0.6	15
407	Gender differences in the treatment of ischemic heart disease. <i>Current Pharmaceutical Design</i> , 2011 , 17, 1059-69	1	8
406	Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. <i>Current Vascular Pharmacology</i> , 2011 , 9, 271-80	1.1	85
405	Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3699-712	1	14
404	Definition of postprandial lipaemia. <i>Current Vascular Pharmacology</i> , 2011 , 9, 292-301	1.1	34
403	Proposing a "lipemic index" as a nutritional and research tool. <i>Current Vascular Pharmacology</i> , 2011 , 9, 313-7	1.1	6
402	Lipid lowering drugs and gallstones: a therapeutic option?. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3622-31		17
401	Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. <i>Current Vascular Pharmacology</i> , 2011 , 9, 62-86	1.1	22
400	Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. <i>Current Vascular Pharmacology</i> , 2011 , 9, 647-57	1.1	29
399	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , 2011 , 9, 531-2	1.1	91
398	Postprandial lipemia in children and adolescents. <i>Current Vascular Pharmacology</i> , 2011 , 9, 318-20	1.1	4
397	Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance. <i>Circulation Journal</i> , 2011 , 75, 2027; author reply 2028	0.7	2
396	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2011 , 31, 730-9	1.7	92

395	Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2011 , 25, 253-7	0.9	5
394	Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in taiwan. <i>Clinical Therapeutics</i> , 2011 , 33, 2091; author reply 2092	0.8	2
393	Impact of statins on glucose metabolism--a matter of debate. <i>American Journal of Cardiology</i> , 2011 , 107, 1866	0.7	4
392	Emerging options in the treatment of dyslipidemias: a bright future?. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 247-70	0.9	13
391	What is the risk of hyperkalaemia in heart failure?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2329-38	0.9	8
390	Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. <i>International Urology and Nephrology</i> , 2011 , 43, 491-8	0.5	28
389	Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. <i>Rheumatology International</i> , 2011 , 31, 153-64	1.2	105
388	Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. <i>Journal of Physiology and Biochemistry</i> , 2011 , 67, 195-204	1	22
387	Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal. <i>Clinical Biochemistry</i> , 2011 , 44, 237-44	0.8	5
386	The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. <i>Current Medical Research and Opinion</i> , 2011 , 27, 1961-1961	0.7	
385	Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. <i>Current Medical Research and Opinion</i> , 2011 , 27, 879-85	0.7	7
384	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011 , 27, 1659-68	0.7	36
383	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2605-11	0.9	24
382	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 1347-53 ^{1.5}		4
381	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2141-2; author reply 2142	0.9	2
380	Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. <i>Current Vascular Pharmacology</i> , 2011 , 9, 258-70	1.1	201
379	Mean platelet volume: a link between thrombosis and inflammation?. <i>Current Pharmaceutical Design</i> , 2011 , 17, 47-58	1	789
378	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , 2011 , 9, 533-7 ^{1.1}		138

377	Does metabolic syndrome influence outcome following percutaneous coronary intervention?. <i>Angiology</i> , 2011 , 62, 437-9	0.6	1
376	Statins and dilated cardiomyopathy: do we have enough data?. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 315-23	1.8	11
375	Review: Antiplatelet drugs: what comes next?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 9-26.8	17	
374	The rationale for lowering the size threshold in elective endovascular repair of abdominal aortic aneurysm. <i>Journal of Endovascular Therapy</i> , 2011 , 18, 308-13	0.5	17
373	A new rapid method to measure human platelet cholesterol: a pilot study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 578-84	0.8	5
372	Peripheral arterial disease and HIV-positive patients. <i>Angiology</i> , 2011 , 62, 7-9	0.6	5
371	What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1835-44	0.9	28
370	Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. <i>Angiology</i> , 2011 , 62, 144-54	0.6	10
369	Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target?. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3644-55	1	21
368	Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association". <i>Stroke</i> , 2011 , 42, e387	1.8	1
367	Liver enzymes: potential cardiovascular risk markers?. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3632-43	1	35
366	Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block?'. <i>Annals of Medicine</i> , 2011 , 43, 249-58	1.2	19
365	Aging men and lipids. <i>American Journal of Men's Health</i> , 2011 , 5, 152-65	0.6	14
364	Point of care testing is appropriate for National Health Service health check. <i>Annals of Clinical Biochemistry</i> , 2011 , 48, 159-65	0.6	20
363	Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis. <i>Vascular</i> , 2011 , 19, 117-20	0.3	12
362	Erythropoietin update 2011. <i>Medical Science Monitor</i> , 2011 , 17, RA240-247	0.8	9
361	Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. <i>Current Vascular Pharmacology</i> , 2011 , 9, 385-400	1.1	22
360	Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. <i>Current Vascular Pharmacology</i> , 2011 , 9, 698-705	1.1	43

359	Rectus sheath hematoma: a simplified emergency surgical approach. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 4-5	0.1	6
358	Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide levels in patients with type 2 diabetes mellitus: a pilot study. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 136-47	0.1	10
357	Are we getting to lipid targets in real life?. <i>Archives of Medical Science</i> , 2010 , 6, 639-41	0.8	14
356	Visfatin/PBEF and atherosclerosis-related diseases. <i>Current Vascular Pharmacology</i> , 2010 , 8, 12-28	1.1	51
355	Involvement of ERK1/2 kinase in insulin-and thrombin-stimulated vascular smooth muscle cell proliferation. <i>Angiology</i> , 2010 , 61, 357-64	0.6	25
354	Should the size threshold for elective abdominal aortic aneurysm repair be lowered in the endovascular era? Yes. <i>Angiology</i> , 2010 , 61, 617-9	0.6	13
353	Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. <i>Angiology</i> , 2010 , 61, 584-90	0.6	15
352	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 723-30	0.9	16
351	eComment: Endovascular repair of ruptured abdominal aortic aneurysms: identifying issues which may be difficult to achieve. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010 , 10, 619	0.4	1
350	Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. <i>Angiology</i> , 2010 , 61, 49-57	0.6	13
349	Are symptomatic patients appropriate candidates for carotid artery stenting? No (at least not at present). <i>Vascular</i> , 2010 , 18, 185-8	0.3	2
348	Cardiac adaptive responses after hypoxia in an experimental model. <i>Angiology</i> , 2010 , 61, 145-56	0.6	20
347	Oxidative stress in the pathogenesis of abdominal aortic aneurysms: a possible pathway for the effect of statins?. <i>Angiology</i> , 2010 , 61, 226-7; author reply 227-8	0.6	4
346	Endovascular abdominal aortic aneurysm repair (EVAR) procedures: counterbalancing the benefits with the costs. <i>Vascular and Endovascular Surgery</i> , 2010 , 44, 319-20	0.3	5
345	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010 , 26, 713-9	0.7	78
344	Aortic pulse wave velocity may have prognostic value not just for hypertension but also for abdominal aortic aneurysms. <i>Hypertension</i> , 2010 , 55, e22; author reply e23	2.4	0
343	The impact of impaired renal function on long-term outcomes in patients with peripheral arterial disease. <i>Angiology</i> , 2010 , 61, 415-6	0.6	5
342	Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 120-34	0.9	43

341	Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010 , 11, 302	0.4	3
340	Association of reduced zinc status with angiographically severe coronary atherosclerosis: a pilot study. <i>Angiology</i> , 2010 , 61, 449-55	0.6	23
339	The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. <i>Current Vascular Pharmacology</i> , 2010 , 8, 437-49	1.1	75
338	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010 , 32, 326-31	0.7	22
337	Severe, but not moderate, carotid atherosclerosis may predict concomitant vascular disease in other arterial beds. <i>Stroke</i> , 2010 , 41, e597; author reply e598	1.8	4
336	Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenti et al. <i>Diabetes Care</i> , 2010 , 33, e132; author reply e133	3.9	2
335	Undertreatment of hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2010 , 26, 439-43	0.7	9
334	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010 , 26, 839-42	0.7	18
333	874 THE REGULATION OF ANGIOTENSIN II-INDUCED CONTRACTION AND NON ADRENERGIC-NON CHOLINERGIC NEUROTRANSMISSION IN HUMAN CORPUS CAVERNOSAL TISSUE: A ROLE FOR LOSARTAN. <i>Journal of Urology</i> , 2010 , 183,	0.6	1
332	Statins and heart failure. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1644-5; author reply 1646	3.8	6
331	Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes. <i>Journal of Vascular Surgery</i> , 2010 , 52, 1367-75	0.7	32
330	The effect of smoking on arterial stiffness. <i>Hypertension Research</i> , 2010 , 33, 398-410	1.1	111
329	Na ⁺ H ⁺ exchanger-1: a link with atherogenesis?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1545-568		6
328	Lone atrial fibrillation: what do we know?. <i>Heart</i> , 2010 , 96, 498-503	1.3	35
327	Takotsubo cardiomyopathy--the current state of knowledge. <i>International Journal of Cardiology</i> , 2010 , 142, 120-5	0.8	67
326	Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. <i>Journal of Psychosomatic Research</i> , 2010 , 69, 179-85	1.2	168
325	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet, The</i> , 2010 , 376, 1916-22	11.5	459
324	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 667-74	0.9	30

323	The role of Toll-like receptors in renal diseases. <i>Nature Reviews Nephrology</i> , 2010 , 6, 224-35	4.3	145
322	Dapagliflozin: more than just another oral glucose-lowering agent?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1581-9	1.8	31
321	Could carbon monoxide and bilirubin be friends as well as foes of the body?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010 , 70, 1-5	0.5	21
320	Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2010 , 8, 820-30	1.1	22
319	Diabetes and antioxidants: myth or reality?. <i>Current Vascular Pharmacology</i> , 2010 , 8, 661-72	1.1	19
318	The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. <i>Current Vascular Pharmacology</i> , 2010 , 8, 792-803	1.1	11
317	Should adipokines be considered in the choice of the treatment of obesity-related health problems?. <i>Current Drug Targets</i> , 2010 , 11, 122-35	0.9	86
316	Vitamin D and metabolic syndrome: is there a link?. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3417-34	1	29
315	Chronic hepatitis C, insulin resistance and vascular disease. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3823-9		3
314	ESVS Guidelines: Section B - diagnosis and investigation of patients with carotid stenosis. <i>Current Vascular Pharmacology</i> , 2010 , 8, 682-91	1.1	8
313	ESVS Guidelines: Section A--prevention in patients with carotid stenosis. <i>Current Vascular Pharmacology</i> , 2010 , 8, 673-81	1.1	30
312	The estrogenic burden on vascular risk in male-to-female transsexuals. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3815-22	1	8
311	Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3939-847	1	8
310	Postoperative atrial fibrillation - what do we really know?. <i>Current Vascular Pharmacology</i> , 2010 , 8, 553-72	1.1	35
309	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010 , 25, 394-8	0.6	21
308	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010 , 25, 406-10	0.6	21
307	Obesity and arterial compliance alterations. <i>Current Vascular Pharmacology</i> , 2010 , 8, 155-68	1.1	49
306	Effects of L-canavanine and ozone on vascular reactivity in septicemic rats. <i>Journal of Physiology and Biochemistry</i> , 2010 , 66, 255-64	1	1

305	Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates. <i>International Urology and Nephrology</i> , 2010 , 42, 711-3	0.5	5
304	Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension. <i>Current Vascular Pharmacology</i> , 2010 , 8, 344-62	1.1	9
303	Management of statin-intolerant high-risk patients. <i>Current Vascular Pharmacology</i> , 2010 , 8, 632-7	1.1	8
302	Endocrine hypertension: diagnosis and management of a complex clinical entity. <i>Current Vascular Pharmacology</i> , 2010 , 8, 646-60	1.1	12
301	The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2010 , 999, 1-13	1.1	3
300	Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome. <i>Open Cardiovascular Medicine Journal</i> , 2010 , 4, 14-9	0.1	20
299	Increased fluorodeoxyglucose uptake following endovascular abdominal aortic aneurysm repair: a predictor of endoleak?. <i>Open Cardiovascular Medicine Journal</i> , 2010 , 4, 117-9	0.1	5
298	Involvement of signaling molecules on na/h exchanger-1 activity in human monocytes. <i>Open Cardiovascular Medicine Journal</i> , 2010 , 4, 181-8	0.1	9
297	Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin. <i>Open Cardiovascular Medicine Journal</i> , 2010 , 4, 297-301	0.1	7
296	Cardiovascular Risk Factors and Peripheral Arterial Disease 2010 , 165-172		
295	The role of polyphenols in cardiovascular disease. <i>Medical Science Monitor</i> , 2010 , 16, RA110-9	0.8	35
294	Kidney function and estimated vascular risk in patients with primary dyslipidemia. <i>Open Cardiovascular Medicine Journal</i> , 2009 , 3, 57-68	0.1	5
293	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009 , 8, 163-84	1	52
292	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1929-37	1.8	10
291	Mortality after first myocardial infarction in Greek patients: a 4-year follow-up study. <i>Angiology</i> , 2009 , 60, 582-7	0.6	3
290	Aortic stiffness in diabetes mellitus--association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 267-74	1.5	9
289	The GALA trial: will it influence clinical practice?. <i>Vascular and Endovascular Surgery</i> , 2009 , 43, 429-32	0.3	11
288	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009 , 5, 16-7		11

287	Dyslipidemia as a risk factor for ischemic stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009 , 9, 1291-7	1.1	55
286	Anti-inflammatory effects of fibrates: an overview. <i>Current Medicinal Chemistry</i> , 2009 , 16, 676-84	1.3	19
285	Serum leptin levels in patients undergoing carotid endarterectomy: a pilot study. <i>Angiology</i> , 2009 , 60, 698-704	0.6	8
284	Irradiation-induced carotid artery stenosis: a preventable complication of neck radiotherapy?. <i>Angiology</i> , 2009 , 60, 273-5	0.6	3
283	Carotid artery stenting may be losing the battle against carotid endarterectomy for the management of symptomatic carotid artery stenosis, but the jury is still out. <i>Vascular</i> , 2009 , 17, 183-9	0.3	10
282	Lipid profile, low-density lipoprotein oxidation and ceruloplasmin in the progeny of families with a positive history of cardiovascular diseases and/or hyperlipidemia. <i>Angiology</i> , 2009 , 60, 455-61	0.6	8
281	Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis?. <i>Angiology</i> , 2009 , 60, 8-11	0.6	4
280	Acute limb ischemia caused by femoral arterial line induces remote liver injury in a rabbit model of liver ischemia/reperfusion injury. <i>Angiology</i> , 2009 , 60, 554-61	0.6	5
279	Percutaneous coronary interventions affect concentrations of interleukin 6 and its soluble receptors in coronary sinus blood in patients with stable angina. <i>Angiology</i> , 2009 , 60, 322-8	0.6	5
278	Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2009 , 23, 130-6	0.9	73
277	The mechanisms of atrial fibrillation in hyperthyroidism. <i>Thyroid Research</i> , 2009 , 2, 4	0.7	62
276	Arteriovenous fistula leading to severe tortuosity and aneurysm formation. <i>Journal of Cardiac Surgery</i> , 2009 , 24, 109	0.3	1
275	HSP 70 and atherosclerosis--protector or activator?. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 307-17	1.5	39
274	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. <i>Clinical Cardiology</i> , 2009 , 32, 230	0.7	3
273	Deterioro de la funci3n renal en la arteriopat3a perif3rica: un par3metro que no debe ser infravalorado. <i>Annals of Vascular Surgery</i> , 2009 , 23, 759-769		
272	Endothelial dysfunction in patients with noncomplicated and complicated hypertension. <i>Clinical and Experimental Hypertension</i> , 2009 , 31, 20-30	0.5	22
271	Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. <i>Lipids in Health and Disease</i> , 2009 , 8, 24	1.3	31
270	Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2692-701	1.5	445

269	Nephroprotective and clinical potential of statins in dialyzed patients. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 541-50	1.5	33
268	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1995-2005	0.7	34
267	Drug-induced fibrotic valvular heart disease. <i>Lancet, The</i> , 2009 , 374, 577-85	11.5	112
266	Anaesthetic techniques for carotid surgery. <i>Lancet, The</i> , 2009 , 373, 807; author reply 807-8	11.5	5
265	Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. <i>Annals of Vascular Surgery</i> , 2009 , 23, 690-9	0.4	32
264	L'insuffisance rñale dans la maladie artfielle pfiphfique : Un paramÈre important qui ne devrait pas Ère nglig. <i>Annales De Chirurgie Vasculaire</i> , 2009 , 23, 749-759		
263	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009 , 24, 351-7	0.6	44
262	Primary and secondary hypertriglyceridaemia. <i>Current Drug Targets</i> , 2009 , 10, 336-43	0.9	23
261	The role of statins for the primary and secondary prevention of coronary heart disease in women. <i>Current Pharmaceutical Design</i> , 2009 , 15, 1054-62	1	17
260	Pleiotropic effects of statins--clinical evidence. <i>Current Pharmaceutical Design</i> , 2009 , 15, 479-89	1	117
259	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. <i>Current Drug Targets</i> , 2009 , 10, 320-7	0.9	23
258	Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. <i>Medical Science Monitor</i> , 2009 , 15, RA203-208	0.8	33
257	Implementation of guidelines for the management of arterial hypertension. The impulsion study. <i>Open Cardiovascular Medicine Journal</i> , 2009 , 3, 26-34	0.1	13
256	The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms. <i>Open Cardiovascular Medicine Journal</i> , 2009 , 3, 48-50	0.1	5
255	Evaluation of aortic stiffness (aortic pulse-wave velocity) before and after elective abdominal aortic aneurysm repair procedures: a pilot study. <i>Open Cardiovascular Medicine Journal</i> , 2009 , 3, 173-5	0.1	15
254	Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. <i>In Vivo</i> , 2009 , 23, 797-812	0.6	17
253	The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. <i>Medical Science Monitor</i> , 2009 , 15, MS12-23	0.8	35
252	Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. <i>Medical Science Monitor</i> , 2009 , 15, MS24-30	0.8	22

251	Effect of statins on renal function in patients with peripheral arterial disease. <i>Vascular and Endovascular Surgery</i> , 2008 , 42, 620-1; author reply 621	0.3	4
250	Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. <i>BJU International</i> , 2008 , 101, 352-9	1.2	37
249	A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. <i>BJU International</i> , 2008 , 101, 1043-7	1.2	13
248	Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. <i>BJU International</i> , 2008 , 102, 108-12	1.2	45
247	Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. <i>American Journal of Cardiology</i> , 2008 , 101, 483-5	0.7	57
246	Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 101, 1679-80	0.7	2
245	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 717-25	0.9	53
244	Orlistat-associated adverse effects and drug interactions: a critical review. <i>Drug Safety</i> , 2008 , 31, 53-65	1.1	217
243	Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview. <i>Annals of Vascular Surgery</i> , 2008 , 22, 481-91	0.4	40
242	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 809-20	1.5	10
241	Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. <i>International Journal of Cardiology</i> , 2008 , 126, 302-12	0.8	167
240	Vascular risk factors in South Asians. <i>International Journal of Cardiology</i> , 2008 , 128, 5-16	0.8	39
239	Obesity and postoperative atrial fibrillation. Is there no connection? Comment on: Wanahita et al. "atrial fibrillation and obesity--results of a meta-analysis". <i>American Heart Journal</i> , 2008 , 156, e5	1.3	4
238	The role of fibrinogen and fibrinolysis in peripheral arterial disease. <i>Thrombosis Research</i> , 2008 , 122, 1-12	1.7	47
237	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , 2008 , 200, 1-12	0.8	63
236	Le diabète joue-t-il un rôle dans les resthoses et les taux de perméabilité après revascularisation artérielle des membres inférieurs? une étude globale critique. <i>Annales De Chirurgie Vasculaire</i> , 2008 , 22, 521-532		
235	Achieving vascular risk factor targets: a survey of a London general practice. <i>Angiology</i> , 2008 , 59, 36-46	0.6	7
234	The peripheral serotonergic pathway: a new target for treating erectile dysfunction?. <i>American Journal of Men's Health</i> , 2008 , 2, 37-9	0.6	2

233	Association between abnormal uterine artery Doppler flow velocimetry, risk of preeclampsia, and indices of arterial structure and function: a pilot study. <i>Angiology</i> , 2008 , 59, 493-9	0.6	13
232	Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. <i>Angiology</i> , 2008 , 59, 137-44	0.6	8
231	Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. <i>Nephron Clinical Practice</i> , 2008 , 108, c56-66		19
230	Smoking, abdominal aortic aneurysms, and ischemic heart disease: is there a link?. <i>Angiology</i> , 2008 , 59, 664-6	0.6	8
229	Statins and heart failure. <i>Angiology</i> , 2008 , 59, 585-615	0.6	9
228	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent. <i>Europace</i> , 2008 , 10, 1266-70	1	32
227	Clinical significance of carotid bruits: an innocent finding or a useful warning sign?. <i>Neurological Research</i> , 2008 , 30, 523-30	0.7	16
226	Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 1209-15	1.5	15
225	Homocysteine activates platelets in vitro. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008 , 14, 8-18	0.8	30
224	Does gender influence the patency of infrainguinal bypass grafts?. <i>Angiology</i> , 2008 , 59, 278-82	0.6	10
223	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 509-15	0.9	94
222	Effect of cardiovascular drugs on adenosine deaminase activity. <i>Angiology</i> , 2008 , 59, 740-4	0.6	8
221	Apolipoprotein E knockout models. <i>Current Pharmaceutical Design</i> , 2008 , 14, 338-51	1	60
220	Experimental Models of Abdominal Aortic Aneurysms: An Overview. <i>Current Pharmaceutical Design</i> , 2008 , 14, 325-337	1	11
219	Cholesterol crystal embolization: a possible complication of peripheral endovascular interventions. <i>Journal of Endovascular Therapy</i> , 2008 , 15, 614-25	0.5	13
218	Are statins an option in the management of abdominal aortic aneurysms?. <i>Vascular and Endovascular Surgery</i> , 2008 , 42, 128-34	0.3	20
217	Soluble but not platelet P-selectin correlates with spontaneous platelet aggregation: a pilot study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008 , 14, 227-33	0.8	7
216	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008 , 15, 693-700	1	20

215	The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008 , 14, 295-302	0.8	12
214	Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2467-76	0.7	15
213	High density lipoprotein cholesterol and statin trials. <i>Current Medicinal Chemistry</i> , 2008 , 15, 2265-70	1.3	10
212	Sodium-lithium countertransport activity in healthy, dyslipidemic, and hypertensive individuals. <i>Angiology</i> , 2008 , 59, 727-35	0.6	1
211	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1593-9	0.7	16
210	Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. <i>Circulation Journal</i> , 2008 , 72, 441-8	0.7	37
209	The role of trimetazidine after acute myocardial infarction. <i>Current Vascular Pharmacology</i> , 2008 , 6, 282-91	0.1	9
208	Additional effects of statins in surgical patients. <i>Annals of Surgery</i> , 2008 , 248, 140-1; author reply 141	1.4	1
207	Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. <i>BJU International</i> , 2008 , 101, 106-12	1.2	42
206	Should a statin be prescribed to every patient with heart failure?. <i>Heart Failure Reviews</i> , 2008 , 13, 211-25	1.3	13
205	Omega-3 fatty acids: how can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008 , 10, 510-7	1.7	13
204	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008 , 23, 370-8	0.6	154
203	¿Qu'papel desempeña la diabetes mellitus en las tasas de reestenosis y permeabilidad tras la revascularización infrainginal? Revisión crítica. <i>Annals of Vascular Surgery</i> , 2008 , 22, 525-536		
202	Acute and long-term antiplatelet therapy. <i>Drugs of Today</i> , 2008 , 44, 331-52	0.5	4
201	Statins and Cholesterol: How Low Can You Go? 2008 , 179-186		
200	Atherogenesis in renal patients: a model of vascular disease?. <i>Current Vascular Pharmacology</i> , 2008 , 6, 93-107	1.1	29
199	Oxidative stress as a common mediator for apoptosis induced-cardiac damage in diabetic rats. <i>Open Cardiovascular Medicine Journal</i> , 2008 , 2, 70-8	0.1	30
198	Impact of lower extremity venous ulcers due to chronic venous insufficiency on quality of life. <i>Open Cardiovascular Medicine Journal</i> , 2008 , 2, 105-9	0.1	12

197	Statin treatment, carotid atherosclerotic plaque macrophage infiltration and circulating inflammatory markers. <i>Open Cardiovascular Medicine Journal</i> , 2008 , 2, 110-4	0.1	10
196	Low HDL cholesterol, smoking and IL-13 R130Q polymorphism are associated with myocardial infarction in Greek Cypriot males. A pilot study. <i>Open Cardiovascular Medicine Journal</i> , 2008 , 2, 52-9	0.1	2
195	Atrial fibrillation as a nonpsychiatric predictor of delirium after cardiac surgery: a pilot study. <i>Medical Science Monitor</i> , 2008 , 14, CR286-291	0.8	20
194	Apolipoprotein J and leptin levels in patients with coronary heart disease. <i>In Vivo</i> , 2008 , 22, 537-42	0.6	20
193	Efficacy of remote ischaemic preconditioning for spinal cord protection against ischaemic injury: association with heat shock protein expression. <i>Folia Neuropathologica</i> , 2008 , 46, 204-12	0.5	19
192	Assessment of lower extremity peripheral arterial disease using a novel automated optical device. <i>Vascular and Endovascular Surgery</i> , 2007 , 41, 522-7	0.3	10
191	The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 3009-20	0.9	6
190	Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2183-92	0.7	69
189	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1169-76	0.7	88
188	Statins: an essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007 , 46, 373-386	0.7	62
187	Serum uric acid as an independent predictor of early death after acute stroke. <i>Circulation Journal</i> , 2007 , 71, 1120-7	0.7	91
186	Gene therapy and erectile dysfunction: the current status. <i>Asian Journal of Andrology</i> , 2007 , 9, 8-15	0.6	12
185	Pheochromocytoma: an update on genetics and management. <i>Endocrine-Related Cancer</i> , 2007 , 14, 935-56		81
184	Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. <i>Clinical Rheumatology</i> , 2007 , 26, 1044-8	1	33
183	Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. <i>Lipids</i> , 2007 , 42, 999-1009	0.7	26
182	Analysis of antihypertensive effects of statins. <i>Current Hypertension Reports</i> , 2007 , 9, 175-83	1.7	24
181	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 118-27	1.2	114
180	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2267-77	0.9	9

179	Optimal medical management of peripheral arterial disease. <i>Vascular and Endovascular Surgery</i> , 2007 , 41, 87	0.3	11
178	Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2459-63	0.9	15
177	Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. <i>Current Pharmaceutical Design</i> , 2007 , 13, 229-39	1	10
176	Optical techniques in the assessment of peripheral arterial disease. <i>Current Vascular Pharmacology</i> , 2007 , 5, 53-9	1.1	39
175	Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 139-47	0.4	17
174	Longitudinal effects of fenfluramine-phentermine use. <i>Angiology</i> , 2007 , 58, 772-3; author reply 774	0.6	
173	Emerging indications for statins: a pluripotent family of agents with several potential applications. <i>Current Pharmaceutical Design</i> , 2007 , 13, 3622-36	1	75
172	Statins and renal function. Is the compound and dose making a difference?. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 963-4; author reply 964	1.2	14
171	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 191-205	1.5	21
170	The prevalence of metabolic syndrome in various populations. <i>American Journal of the Medical Sciences</i> , 2007 , 333, 362-71	0.6	153
169	Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. <i>Angiology</i> , 2007 , 58, 689-97	0.6	113
168	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1143-60	1.5	27
167	Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. <i>Angiology</i> , 2007 , 58, 329-35	0.6	32
166	Platelet activation in bypass surgery for critical limb ischemia. <i>Vascular and Endovascular Surgery</i> , 2007 , 41, 322-9	0.3	3
165	The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007 , 13, 35-42	0.8	7
164	Statins and regression of coronary atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2197; author reply 2197	7.4	6
163	Association between the Taq1B polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 1190-8	1.5	16
162	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 53-72	1.2	81

161	Serotonin induces a biphasic response in rabbit cavernosal smooth muscle: relevance to the erectile process. <i>Urologia Internationalis</i> , 2007 , 79, 255-61	0.4	5
160	Prospective assessment of lower-extremity peripheral arterial disease in diabetic patients using a novel automated optical device. <i>Angiology</i> , 2007 , 58, 579-85	0.6	22
159	Coagulation, platelets, and acute pancreatitis. <i>Pancreas</i> , 2007 , 34, 15-20	0.6	43
158	Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. <i>Current Drug Targets</i> , 2007 , 8, 942-51	0.9	38
157	The effect of statins on postprandial lipemia. <i>Current Drug Targets</i> , 2007 , 8, 551-60	0.9	25
156	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <i>Current Drug Targets</i> , 2007 , 8, 483-8	0.9	23
155	The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 642-52	0.8	35
154	Thromboangiitis obliterans (Buerger's disease): searching for a therapeutic strategy. <i>Angiology</i> , 2007 , 58, 75-84	0.6	25
153	Metallothionein expression in the high-risk carotid atherosclerotic plaque. <i>Current Medical Research and Opinion</i> , 2007 , 23, 659-70	0.7	18
152	Peripheral Arterial Disease and Emerging Biochemical Vascular Risk Factors 2007 , 111-116		
151	Lipids and Peripheral Arterial Disease 2007 , 35-40		
150	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , 2007 , 1, 8-14	0.1	22
149	Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. <i>In Vivo</i> , 2007 , 21, 685-94	0.6	14
148	Gender influence on postprandial lipemia in heterozygotes for familial hypercholesterolemia. <i>Annals of Clinical and Laboratory Science</i> , 2007 , 37, 335-42	0.2	11
147	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. <i>Lipids</i> , 2006 , 41, 647-54	0.7	66
146	The effect of cholesterol-lowering treatment on renal function. <i>American Journal of Kidney Diseases</i> , 2006 , 47, 561; author reply 562	2.2	10
145	Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 1-15	0.9	30
144	Definitions of metabolic syndrome: Where are we now?. <i>Current Vascular Pharmacology</i> , 2006 , 4, 185-97	1.1	31

143	The management of phosphodiesterase-5 (PDE5) inhibitor failure. <i>Current Vascular Pharmacology</i> , 2006 , 4, 89-93	1.1	29
142	The role of thiols in liver ischemia-reperfusion injury. <i>Current Pharmaceutical Design</i> , 2006 , 12, 2891-901	1	36
141	Lipid lowering therapy in the elderly: is there a benefit?. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3945-60		6
140	Heparin therapy leads to platelet activation and prolongation of platelet function analyser-100 closure time. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 156-7	0.9	0
139	Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?. <i>Platelets</i> , 2006 , 17, 1-6	0.9	39
138	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp. <i>Diabetes Care</i> , 2006 , 29, 2561-2568	3.9	6
137	Dyslipidaemia, hypercoagulability and the metabolic syndrome. <i>Current Vascular Pharmacology</i> , 2006 , 4, 175-83	1.1	37
136	Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 851-66	1.5	24
135	Alcohol use, vascular disease, and lipid-lowering drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 1-7	1.1	23
134	Management of a patient with a null low-density lipoprotein receptor mutation: a case report. <i>Angiology</i> , 2006 , 57, 729-32	0.6	11
133	The role of serotonin (5-hydroxytryptamine _{1A} and 1B) receptors in prostate cancer cell proliferation. <i>Journal of Urology</i> , 2006 , 176, 1648-53	0.6	69
132	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006 , 22, 873-83	0.7	191
131	Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2037-9	0.7	7
130	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. <i>Current Medical Research and Opinion</i> , 2006 , 22, 511-28	0.7	49
129	The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 211-21	0.9	31
128	Doxazosin and serotonin (5-HT) receptor (1A, 2A, and 4) antagonists inhibit 5-HT-mediated human cavernosal contraction. <i>Journal of Andrology</i> , 2006 , 27, 679-85		16
127	Treating to target patients with primary hyperlipidaemia: comparison of the effects of atorvastatin and rosuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006 , 22, 1123-31	0.7	55
126	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 1293-301	2.7	208

125	Metabolic syndrome and gender differences in postprandial lipaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006 , 13, 661-4		28
124	Exorcising ghosts and unwelcome guests. <i>Annals of Internal Medicine</i> , 2006 , 144, 149	2.5	1
123	Smooth muscle and purinergic contraction of the human, rabbit, rat, and mouse testicular capsule. <i>Biology of Reproduction</i> , 2006 , 74, 473-80	0.9	29
122	Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. <i>Current Drug Targets</i> , 2006 , 7, 761-71	0.9	27
121	The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. <i>BJU International</i> , 2006 , 97, 634-9	1.2	58
120	Statins and peripheral arterial disease: potential mechanisms and clinical benefits. <i>Annals of Vascular Surgery</i> , 2006 , 20, 696-705	0.4	38
119	Cardiovascular Risk Factors and Peripheral Arterial Disease 2006 , 133-140		
118	Atrial fibrillation, inflammation and statins. <i>Hellenic Journal of Cardiology</i> , 2006 , 47, 51-3	0.5	7
117	New-onset diabetes after transplantation. <i>Lancet, The</i> , 2005 , 365, 1766	11.5	3
116	Re: the prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. <i>Journal of Urology</i> , 2005 , 173, 1050	0.6	2
115	Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study. <i>Platelets</i> , 2005 , 16, 261-7	0.9	6
114	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005 , 21, 231-44.7	4.7	34
113	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. <i>Platelets</i> , 2005 , 16, 65-71	0.9	23
112	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005 , 54, 1065-74	2.7	56
111	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1157-9.7	9.7	138
110	The role of serotonin in tumour growth (Review). <i>Oncology Reports</i> , 2005 , 14, 1593	1.3	4
109	In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. <i>BJU International</i> , 2005 , 96, 1424	1.2	
108	Endothelin-1 and human platelets. <i>Current Vascular Pharmacology</i> , 2005 , 3, 393-9	1.1	22

107	Lipid-lowering therapy in patients with peripheral arterial disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005 , 10, 145-7	0.9	13
106	Mean platelet volume in patients with type 2 diabetes mellitus. <i>Platelets</i> , 2005 , 16, 219-20; author reply 221	0.9	6
105	Risk modification in patients with peripheral arterial disease: a retrospective survey. <i>Angiology</i> , 2005 , 56, 279-87	0.6	33
104	Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri P. Mikhailidis Associate Editor: Stella S. Daskalopoulou)]. <i>Current Pharmaceutical Design</i> , 2005 , 11, 4115-4116	1	
103	Clinical relevance of postprandial lipaemia. <i>Current Medicinal Chemistry</i> , 2005 , 12, 1931-45	1.3	104
102	Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. <i>Stroke</i> , 2005 , 36, 1372-6	1.8	94
101	Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005 , 11, 139-46	0.8	14
100	Fenofibrate: metabolic and pleiotropic effects. <i>Current Vascular Pharmacology</i> , 2005 , 3, 87-98	1.1	53
99	Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. <i>Current Medicinal Chemistry</i> , 2005 , 12, 443-52	1.3	44
98	Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. <i>Angiology</i> , 2005 , 56, 663-70	0.6	21
97	Early statin therapy in patients with acute coronary syndrome. <i>Hellenic Journal of Cardiology</i> , 2005 , 46, 5-8	0.5	2
96	Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?. <i>Anticancer Research</i> , 2005 , 25, 4281-6	0.6	20
95	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. <i>Hellenic Journal of Cardiology</i> , 2005 , 46, 380-6	0.5	17
94	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004 , 20, 627-37	0.7	62
93	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1691-1701	0.7	72
92	The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. <i>Angiology</i> , 2004 , 55, 53-62	0.6	71
91	Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004 , 10, 9-18	0.8	12
90	Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004 , 9, 27-33	0.9	54

89	Erectile dysfunction: a need for greater awareness. <i>Perspectives in Public Health</i> , 2004 , 124, 214-6		3
88	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , 2004 , 66, 1714-5	2.7	24
87	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 589-99	2.2	188
86	The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia. <i>Journal of Women's Health</i> , 2004 , 13, 1119-26	1	15
85	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1385-92	0.7	12
84	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. <i>Platelets</i> , 2004 , 15, 117-25	0.9	61
83	Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. <i>Fertility and Sterility</i> , 2004 , 81, 1624-31	1.3	12
82	Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies. <i>Vascular Disease Prevention</i> , 2004 , 1, 243-253		14
81	The effect of alcohol and gemfibrozil co-administration in Wistar rats. <i>In Vivo</i> , 2004 , 18, 49-53	0.6	4
80	Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells. <i>Anticancer Research</i> , 2004 , 24, 2853-9 ⁶	0.6	31
79	Gamma-glutamyltransferase and vascular disease. <i>Clinical Chemistry</i> , 2003 , 49, 522-3; author reply 523	1.4	5
78	Mean platelet volume as an indicator of platelet activation: methodological issues. <i>Platelets</i> , 2003 , 14, 335-6	0.9	27
77	Direct measurement of hepatic tissue hypoxia by using a novel tcpO2/pCO2 monitoring system in comparison with near-infrared spectroscopy. <i>Liver International</i> , 2003 , 23, 163-70	1.7	15
76	More on PROSPER. <i>Lancet, The</i> , 2003 , 361, 1135-6; author reply 1136	11.5	10
75	Influence of platelet count and activity on thromboelastography parameters. <i>Platelets</i> , 2003 , 14, 219-24 ^{0.9}	0.9	74
74	Early vascular benefits of statin therapy. <i>Current Medical Research and Opinion</i> , 2003 , 19, 540-56	0.7	132
73	Influence of smoking on predictors of vascular disease. <i>Angiology</i> , 2003 , 54, 507-30	0.6	111
72	Value of thromboelastography in the assessment of platelet function. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003 , 9, 137-42	0.8	50

71	Apolipoprotein E polymorphism and atherosclerosis. <i>Angiology</i> , 2003 , 54, 59-71	0.6	41
70	The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population--implications for the interpretation of similar studies. <i>Angiology</i> , 2003 , 54, 51-8	0.6	23
69	The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003 , 9, 115-20	0.8	23
68	Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. <i>Journal of Biological Chemistry</i> , 2003 , 278, 8877-80	1.4	103
67	Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. <i>Platelets</i> , 2003 , 14, 15-20	0.9	41
66	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2003 , 19, 615-7	0.7	57
65	Platelets as predictors of vascular risk: is there a practical index of platelet activity?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003 , 9, 177-90	0.8	198
64	The effects of lipid-regulating therapy on haemostatic parameters. <i>Current Pharmaceutical Design</i> , 2003 , 9, 2425-43	1	30
63	The effect of graded systemic hypoxaemia on hepatic tissue oxygenation. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 540, 317-23	0.9	2
62	The Effect of Clopidogrel (Plavix) on Platelet Function in Patients with Peripheral Vascular Disease - Comparison with Aspirin. <i>Journal of Cardiac Surgery</i> , 2002 , 17, 563-563	0.3	2
61	Decreased urinary bladder apoptosis in a rabbit model of diabetes mellitus. <i>Urological Research</i> , 2002 , 30, 79-83		5
60	Statins and renal function. <i>Angiology</i> , 2002 , 53, 493-502	0.6	83
59	Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002 , 18, 499-502	0.7	15
58	Regarding "Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report". <i>Angiology</i> , 2002 , 53, 243	0.6	1
57	Effect of ciprofibrate on C-reactive protein and fibrinogen levels. <i>Angiology</i> , 2002 , 53, 273-7	0.6	45
56	Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002 , 8, 381-2	0.8	1
55	A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. <i>Cardiovascular Research</i> , 2002 , 54, 528-38	2.5	125
54	Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002 , 7, 219-26	0.9	29

53	Beyond LDL-C--the importance of raising HDL-C. <i>Current Medical Research and Opinion</i> , 2002 , 18, 36-44	0.7	33
52	Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. <i>Clinical Science</i> , 2002 , 103 Suppl 48, 459S-463S	1.7	3
51	A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2002 , 77, 945-51	1.3	64
50	The choice of antihypertensive drugs in patients with erectile dysfunction. <i>Current Medical Research and Opinion</i> , 2002 , 18, 103-7	0.7	24
49	Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <i>International Journal of Cardiology</i> , 2002 , 84, 53-7	0.8	41
48	The effect of nitric oxide and peroxyntirite on rabbit cavernosal smooth muscle relaxation. <i>World Journal of Urology</i> , 2001 , 19, 220-4	0.8	36
47	The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. <i>European Journal of Pharmacology</i> , 2001 , 425, 57-64	1.6	48
46	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. <i>Journal of Diabetes and Its Complications</i> , 2001 , 15, 211-26	0.9	23
45	Effect of atorvastatin on serum creatinine levels. <i>Current Medical Research and Opinion</i> , 2001 , 17, 230-1	0.7	22
44	Measurement of atherosclerosis progression. <i>Lancet, The</i> , 2001 , 358, 329-30	11.5	0
43	Smoking diminishes the beneficial effect of statins: observations from the landmark trials. <i>Angiology</i> , 2001 , 52, 575-87	0.6	46
42	Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 1385-6	2.7	2
41	Drug treatment of combined hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 327-36	0.9	18
40	The Treatment of Coronary Heart Disease: An Update Part 5: Selected Comments and Questions Compiled by. <i>Current Medical Research and Opinion</i> , 2001 , 17, 41-42	0.7	
39	Endothelin-1 and Urinary Bladder Hyperplasia Following Partial Bladder Outlet Obstruction. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, S262-S263	0.8	3
38	Relaxation of rabbit lower urinary tract smooth muscle by nitric oxide and carbon monoxide: modulation by hydrogen peroxide. <i>European Journal of Pharmacology</i> , 2000 , 387, 329-35	1.6	15
37	Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. Potential clinical relevance. <i>Urological Research</i> , 2000 , 28, 116-21		13
36	Altered Cavernosal Endothelin-B-Receptor Binding Sites in the Rabbit Model of Partial Bladder Outlet Obstruction. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, S260-S261	0.8	

35	The molecular basis of penile erection. <i>Current Medical Research and Opinion</i> , 2000 , 16 Suppl 1, s21-30	0.7	4
34	The use of citrated whole blood in thromboelastography. <i>Anesthesia and Analgesia</i> , 2000 , 90, 1086-8	1	78
33	Sildenafil: a urologist's view. <i>Current Medical Research and Opinion</i> , 2000 , 16 Suppl 1, s48-58	0.7	4
32	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. <i>Current Medical Research and Opinion</i> , 2000 , 16, 139-146	0.7	48
31	The treatment of hypertension in patients with erectile dysfunction. <i>Current Medical Research and Opinion</i> , 2000 , 16 Suppl 1, s31-6	0.7	19
30	Natural statins and stroke. <i>Circulation</i> , 2000 , 101, E45	4.8	1
29	Possible role of endothelin-1 in the rabbit urinary bladder hyperplasia secondary to partial bladder outlet obstruction. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000 , 34, 15-20		11
28	Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. <i>Current Medical Research and Opinion</i> , 2000 , 16, 21-32	0.7	25
27	Regarding "smoking is associated with dose-related increase of intima-media thickness and endothelial dysfunction". <i>Angiology</i> , 1999 , 50, 959-61	0.6	6
26	Time-dependent up-regulation of neuronal 5-hydroxytryptamine binding sites in the detrusor of a rabbit model of partial bladder outlet obstruction. <i>World Journal of Urology</i> , 1999 , 17, 255-60	0.8	13
25	Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance. <i>World Journal of Urology</i> , 1999 , 17, 290-5	0.8	24
24	Differential alterations of spontaneous and stimulated ⁴⁵ Ca(2+) uptake by platelets from patients with type I and type II diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1999 , 13, 271-6	0.9	2
23	Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. <i>International Journal of Cardiology</i> , 1999 , 69, 237-44	0.8	48
22	Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. <i>Nephron</i> , 1999 , 83, 261-7	0.7	15
21	Endothelin and erectile dysfunction: a target for pharmacological intervention?. <i>Expert Opinion on Investigational Drugs</i> , 1998 , 7, 1759-67	1.8	11
20	Cigarette smoking and erectile dysfunction. <i>Perspectives in Public Health</i> , 1998 , 118, 151-5		42
19	Unstable angina. <i>American Heart Journal</i> , 1996 , 131, 1234-5	1.3	
18	Triacylglycerol lowering properties of the adenosine analog GR 79236 during 5 days of dosing large, old rats: A pilot study. <i>Nutrition Research</i> , 1996 , 16, 1925-1932	1.4	1

17	Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. <i>Clinica Chimica Acta</i> , 1994 , 230, 157-67	1.6	22
16	Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. <i>Journal of Hepatology</i> , 1994 , 21, 1017-22	3.5	18
15	Improvement of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR 79236. <i>Clinical Science</i> , 1994 , 86, 593-8	1.7	13
14	Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and $^{45}\text{Ca}^{2+}$ uptake by human platelets. <i>European Journal of Pharmacology</i> , 1993 , 245, 67-73		18
13	Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. <i>Thrombosis Research</i> , 1993 , 71, 227-36	1.7	29
12	A thesis for all seasons. <i>Nature</i> , 1991 , 353, 789-90	16.4	13
11	Differential inhibitory potencies of non-steroidal antiinflammatory drugs on smooth muscle prostanoid synthesis. <i>European Journal of Pharmacology</i> , 1990 , 182, 83-9	1.6	14
10	Muscarinic stimulation of prostanoid synthesis by the isolated rat trachea: calcium dependency and effect of cortisol and cigarette smoke. <i>European Journal of Pharmacology</i> , 1989 , 160, 107-15	1.6	6
9	Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity. <i>FEBS Letters</i> , 1989 , 245, 105-9	1.1	37
8	Ethanol ingestion inhibits human whole blood platelet impedance aggregation. <i>American Journal of Clinical Pathology</i> , 1987 , 88, 342-5	0.5	34
7	Cyclosporine A enhances platelet aggregation. <i>Kidney International</i> , 1987 , 32, 889-95	2.7	96
6	Muscarinic stimulation of prostacyclin synthesis by the rat penis. <i>European Journal of Pharmacology</i> , 1986 , 123, 67-71	1.6	21
5	Thromboxane A2 analogue (U-46619) stimulates vascular PGI ₂ synthesis. <i>European Journal of Pharmacology</i> , 1985 , 107, 259-62	1.6	51
4	Adrenergic modulation of vascular prostacyclin (PGI ₂) secretion. <i>European Journal of Pharmacology</i> , 1985 , 114, 33-40	1.6	60
3	Effect of nonesterified fatty acids on the stability of prostacyclin activity. <i>Metabolism: Clinical and Experimental</i> , 1983 , 32, 717-21	2.7	65
2	Epidemiology and Pathophysiology of Carotid Artery Disease1-7		
1	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> ,	1.9	3